Nuvalent Trades Close to $124 After GSK’s $10.6 Billion Offer

Nuvalent surged Tuesday after GSK said it would buy the Nasdaq-listed biotech for $10.6 billion, or $124 a share in cash. The stock shot up 38.9% to $122.93, almost reaching the offer price and trading like the day’s standard merger-arb play.

GSK beats 2025 sales targets — but new CEO warns 2026 growth will cool

GSK beats 2025 sales targets — but new CEO warns 2026 growth will cool

GSK is projecting slower sales growth in 2026 under new CEO Luke Miels, who took over from Emma Walmsley earlier this year. The company is bracing for patent expiries on its leading HIV drugs starting in 2028. It now expects revenue growth of 3% to 5% at constant currency, while warning that vaccines and general medicines sales might decline. Shares climbed 1.4% by 0809 GMT after an initial drop. Core earnings per share for Q4 came in at 25.5 pence, supported by an 8% sales increase to £8.62 billion.
4 February 2026
1 2 3 4

US Stock Market Today Updates

MARKET CALENDAR

Key Events Today

The catalysts most likely to move markets.

#1

Warsh at Jackson Hole

Policy tone can move rates, USD, equities, gold and crypto simultaneously.

#2

Michigan sentiment

A weak final reading or elevated inflation expectations could pressure risk assets.

#3

Chicago PMI

A surprise versus 58.0 may alter the near-term manufacturing-growth narrative.

View full calendar
Times and estimates may change. Verify before trading.